Business Context and Reporting Period
This Form 8-K was filed by Novus Therapeutics, Inc. (not Eledon Pharmaceuticals, Inc., as indicated in the metadata) on February 13, 2020. The report details a corporate transaction involving the exchange of common stock for newly designated preferred stock.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial data points relate to the capital structure transaction:
- Shares Exchanged: 3,796,000 shares of Common Stock.
- Preferred Stock Issued: 3,796 shares of Series X Convertible Preferred Stock.
- Expense Reimbursement: Up to $25,000 to the exchanging stockholders.
- Post-Transaction Capitalization: 16,069,562 shares of Common Stock outstanding and 3,796 shares of Series X Preferred Stock outstanding.
Material Changes
The material change reported is the execution of an Exchange Agreement with Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., and Biotechnology Value Trading Fund OS, L.P. Key changes include:
- Conversion of 3,796,000 common shares into 3,796 shares of Series X Preferred Stock.
- Each share of Series X Preferred Stock is convertible into 10,000 shares of Common Stock.
- Implementation of a "conversion blocker" preventing holders from converting if it would result in beneficial ownership exceeding 9.99% of total Common Stock.
- Series X Preferred Stock holders participate pari passu with Common Stock holders in liquidation events.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, revenue outlook, or management commentary regarding future operations. The transaction was executed under Section 3(a)(9) of the Securities Act of 1933 as an unregistered sale of equity securities. The exchange was scheduled to complete on or about February 19, 2020.
Investor Verification Checklist
- Verify the correct registrant name is Novus Therapeutics, Inc. (NVUS), not Eledon Pharmaceuticals.
- Confirm the total outstanding share count post-exchange (16,069,562 Common + 3,796 Series X Preferred).
- Review the attached Certificate of Designations (Exhibit 3.1) for full terms of the Series X Preferred Stock.
- Check the Exchange Agreement (Exhibit 10.1) for specific limitations on the conversion blocker and voting rights.